Je pagina wordt geladen…
European journal of clinical pharmacology
Door Alharran AM, Alsaleeli KM, Alkhamis AS en 9 anderen.
Inhoud in het Engels
To compare the efficacy and safety of levetiracetam versus valproate in children with new-onset or previously treated but inadequately controlled epilepsy.
Ward zet deze artikelen in dezelfde app als je kaarten en vragen. Eén gratis account voor Ward, Suture, Osler en Prognia.
We systematically searched PubMed, Scopus, Web of Science, and Cochrane Library from inception to April 2026 for randomized controlled trials (RCTs) comparing levetiracetam versus valproate in children (aged 0-18 years) with new-onset or previously treated but inadequately controlled epilepsy. Outcomes included seizure freedom, exploratory analyses of survival time without seizure and time to first seizure recurrence, change in aspartate aminotransferase (AST) levels, and adverse events.
Eight RCTs involving 1,000 participants were included. Seizure freedom did not differ significantly between treatments (5 studies, 655 participants; RR = 0.95, 95% CI: 0.83-1.09; P = 0.45; I² = 59.5%; low-certainty evidence). Exploratory time-related outcomes favored valproate but were limited by low-certainty evidence and inadequate handling of censoring. Levetiracetam was associated with lower AST levels, although this did not establish superior hepatic safety, and with fewer overall adverse events and less weight gain.
No significant difference in seizure freedom was detected between levetiracetam and valproate, although the low-certainty finding was sensitive to one trial. Time-related outcomes favored valproate but were exploratory and limited by inadequate handling of censoring. Levetiracetam was associated with fewer overall adverse events and less weight gain, while behavioral and hepatic safety remained uncertain. Treatment should be individualized based on patient and medication-related factors.
Gepubliceerd in European journal of clinical pharmacology. Het abstract staat hier zoals het is gepubliceerd en blijft het werk van de auteurs; lees het volledige artikel bij de bron.
Prognia toont dit artikel als naslag en voor onderwijs. Het is geen medisch advies. Lees altijd het origineel en volg de actuele richtlijnen en lokale protocollen voordat je ernaar handelt.
